Journal Title：Immunotherapy

Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.

Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.

為了充分利用新興機會，免疫系統(tǒng)的許多方面和免疫調(diào)節(jié)療法的機制仍有待闡明。參與免疫療法研究和臨床應用的人員面臨著來自這個快速發(fā)展的領域的大量復雜知識的挑戰(zhàn)。《免疫療法》雜志為科學界提供了一個跨學科論壇，以簡明扼要的格式為他們提供有關免疫療法各個方面最新進展的信息，以幫助他們駕馭這個復雜的領域。

《免疫療法》以簡明扼要、一目了然的文章格式提供重要信息。國際專家報告和分析了該領域的關鍵進展，為這個至關重要的研究領域提供了一個權威但易于理解的論壇。歡迎主動提交文章提案，作者必須完全遵守該期刊的披露和利益沖突政策以及主要出版指南，包括 ICMJE 和 GPP3。

Immunotherapy創(chuàng)刊于2009年，由Future Medicine Ltd.出版商出版，收稿方向涵蓋醫(yī)學 - 免疫學全領域，此期刊水平偏中等偏靠后，在所屬細分領域中專業(yè)影響力一般，過審相對較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機率較高。平均審稿速度 較慢,6-12周 ，影響因子指數(shù)2.7，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。